Eli Lilly ups 2024 sales view on weight-loss drug demand
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion today, lifting its shares nearly 6%.
Business
• 30 Apr 24
